Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (4) , 574-578
- https://doi.org/10.1093/jac/dki032
Abstract
Objectives: To evaluate the activity of daptomycin tested against numerous species of viridans group streptococci and Streptococcus bovis, which are associated with wound infections, sepsis, cellulitis, endocarditis, abscesses and dental caries. The incidence of penicillin-resistant (non-susceptible) and MLSB-resistant strains among viridans group streptococci often varies by species. Methods: The activity of daptomycin was compared with seven other antimicrobial classes using reference broth microdilution and disc diffusion methods tested against 915 bacteraemic isolates of streptococci (815 viridans group strains; 100 S. bovis). Results: Among all species of viridans group streptococci and S. bovis, 99.9% of isolates were susceptible to daptomycin (MIC values, ≤ 0.016–2 mg/L). In contrast, penicillin, erythromycin and tetracycline susceptibility varied widely between species. Erythromycin susceptibility was in the range 48.6–88.7%, penicillin susceptibility in the range 65.5–98.1% and tetracycline in the range 35.0–93.9%. The inter-method agreement between daptomycin and linezolid resistance (comparison agent) disc diffusion and broth microdilution test results was high, each showing near complete susceptibility (99.9%). Conclusions: Daptomycin is an active antimicrobial agent that has a usable potency against eight species of viridans group streptococci, as well as S. bovis, with all MIC values at ≤2 mg/L.Keywords
This publication has 10 references indexed in Scilit:
- The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure InfectionsClinical Infectious Diseases, 2004
- Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid BiosynthesisAntimicrobial Agents and Chemotherapy, 2003
- Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001Antimicrobial Agents and Chemotherapy, 2003
- Daptomycin: a novel lipopeptide antibioticClinical Microbiology Newsletter, 2002
- Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.Journal of Antimicrobial Chemotherapy, 2001
- The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolatesJournal of Antimicrobial Chemotherapy, 2001
- Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin AmericaClinical Microbiology & Infection, 2001
- Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro testsDiagnostic Microbiology and Infectious Disease, 2000
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendationsAntimicrobial Agents and Chemotherapy, 1987